Two hundred seventy-seven patients with chronic Lyme disease were treated with tetracycline for 1 to 11 months (mean, 4 months); the outcomes for these patients were generally good. Overall, 20% of the patients were cured; 70% of the patients' conditions improved, and treatment failed for 10% of the patients. Improvement frequently did not take place for several weeks; after 2 months of treatment, 33% of the patients' conditions were significantly improved (degree of improvement, 75%-100%), and after 3 months of treatment, 61% of the patients' conditions were significantly improved. Treatment outcomes for seronegative patients (20% of all patients) were similar to those for seropositive patients. Western immunoblotting showed reactions to one or more Borrelia burgdorferi-specific proteins for 65% of the patients for whom enzyme-linked immunosorbent assays were negative. Whereas age, sex, and prior erythema migrans were not correlated with better or worse treatment outcomes, a history of longer duration of symptoms or antibiotic treatment was associated with longer treatment times to achieve improvement and cure. These results support the use of longer courses of treatment in the management of patients with chronic Lyme disease. Controlled trials need to be conducted to validate these observations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1086/516171 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unlabelled: The spirochete causes Lyme disease. In some patients, an excessive, dysregulated proinflammatory immune response can develop in joints leading to persistent arthritis. In such patients, persistence of antigenic peptidoglycan (PG ) fragments within joint tissues may contribute to the immunopatho-genesis, even after appropriate antibiotic treatment.
View Article and Find Full Text PDFOptimizing Exclusion Criteria for Clinical Trials of Persistent Lyme Disease Using Real-World Data.
Healthcare (Basel)
December 2024
Union Square Medical Associates, 595 Buckingham Way, Suite 350, San Francisco, CA 94132, USA.
Background/objectives: Although eligibility criteria for clinical trials significantly impact study outcomes, these criteria are often established without scientific justification, leading to delayed recruitment, small sample sizes, and limited study generalizability. Persistent Lyme disease (PLD) presents unique challenges due to symptom variability, inconsistent treatment responses, and the lack of reliable biomarkers, underscoring the need for scientifically justified eligibility criteria.
Objective: This study examines the effects of commonly used enrollment criteria on sample yield in PLD clinical trials using real-world data (RWD) from the MyLymeData patient registry.
Examining Infant and Child Neurodevelopmental Outcomes After Lyme Disease During Pregnancy.
Pathogens
November 2024
Zickler Family Prenatal Pediatrics Institute, Children's National Hospital, Washington, DC 20010, USA.
Lyme disease is the most common vector-borne disease in the United States. Recent environmental and socioecological changes have led to an increased incidence of Lyme and other tick-borne diseases, which enhances the urgency of identifying and mitigating adverse outcomes of Lyme disease exposure. Lyme disease during pregnancy, especially when untreated, may lead to adverse pregnancy and neonatal outcomes; however, long-term child outcomes following utero exposure to Lyme disease have not yet been systematically assessed.
View Article and Find Full Text PDFTransendothelial migration of the Lyme disease spirochete involves spirochete internalization as an intermediate step through a transcellular pathway that involves Cdc42 and Rac1.
Microbiol Spectr
December 2024
Department of Biochemistry & Molecular Biology, University of Calgary, Calgary, Alberta, Canada.
Despite its importance in pathogenesis, the hematogenous dissemination pathway of is still largely uncharacterized. To probe the molecular details of transendothelial migration more easily, we studied this process using cultured primary or telomerase-immortalized human microvascular endothelial cells in a medium that maintains both the human cells and the spirochetes. In -infected monolayers, we observed ~55% of wild-type spirochetes crossing the monolayer.
View Article and Find Full Text PDFDisparities in Peripheral Artery Disease-related Mortality in Chronic Inflammatory Disease in the United States from 1999 to 2020.
Curr Cardiol Rev
December 2024
Keele Cardiovascular Research Group, Keele University, Newcastle-under-Lyme, UK.
Introduction: Peripheral arterial disease (PAD) is a marker of significant atherosclerotic cardiovascular disease and is associated with greater healthcare burden and worse prognosis in individuals with chronic inflammatory disease (CID). We aimed to investigate temporal trends and disparities of PAD-related mortality in populations with CID from 1999-2020 across six common CIDs (i.e.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!